Testosterone Found to Cause Heart Attacks in Obese Smokers With Heart Disease
by Jeffrey Dach MD
This article is Part One, For Part Two Click Here.
For part three click here.
How Not to Do a Testosterone Clinical Trial
A testosterone study by Shalender Bhasin of the Boston University School of Medicine published in the New England Journal was halted early because the testosterone treated group had more heart attacks.(1)
The study participants were a very skewed population of immobilized, elderly, obese, men with underlying heart disease. Most were heavy smokers with advanced heart disease on Lipitor and blood pressure meds. These results are opposite to decades of research showing testosterone benefits the heart. I would suggest that giving virtually anything to these men to get them moving around would cause the same increase in heart attack rate. (1)(2)(3)(4) Above left image : photo of obese smoker courtesy of Huffington Post.
Sending Old Men Up the Hill
If we recruited a group of immobilized, obese, elderly frail men with heart disease, and then instructed them to run up a mountain hill, they would be unable to go more than a few steps, and no harm would come from it. However, if this same group used testosterone gel for a few weeks, the testosterone would give them the leg muscle strength to run up the hill and many would succumb to heart attacks. This is a nutshell is what happened in the New England Journal, Bhasin study. Again, I would suiggest that virtually any drug stimulation would accomplish the same increase heart attack risk, simply by making the men more active.
Decades of Research Shows Health Benefits of Testosterone
Low Testosterone Is Associated with Increased Mortality
Three separate population studies have shown that low testosterone levels is associated with 40% increased cardiovascular mortality. (5)(6)(7) A study by Malkin published in Heart followed 900 men over 8 years with known coronary artery disease. The men with low testosterone had 22% mortality compared to only 12 % for men with normal testosterone levels, almost double the mortality rate for the low testosterone group.
Testosterone Improves Time to Cardiac Ischemia on Treadmill Test
In addition, multiple studies over decades have shown testosterone is beneficial in men with coronary artery disease by prolonging time to cardiac ischemia. An elegant study by English et al. showed the testosterone group showed longer times on the treadmill before reaching abnormal EKG changes or chest pain (angina). This indicates improved blood flow in the coronary artery circulation, a benefit of testosterone. (8)(9)(10)(11)
Testosterone Benefits For Heart Failure Patients
Dr Morgentaler to the Rescue
A more reasonable approach for testosterone replacement is described by Morgentaler in his 2007 commentary, “Guidelines for Male Testosterone Therapy: A Clinician’s Perspective.”
Abraham Morgentaler is a Harvard trained Urologist, who says he was taught in medical school that low testosterone was rare and treatment ineffective. Once he started clinical practice in 1988, he was surprised to find that many of his patients had low testosterone associated with erectile dysfunction (ED) which greatly improved with testosterone injections. Patients thanked him for finally “feeling normal again.” Nowadays in 2010, testosterone is accepted treatment for diminished libido and erectile dysfunction (ED). Dr Morgentaler actually prefers to start with transdermal gel testosterone before using the Viagra and Cialis type drugs, (the phosphodiesterase type-5 inhibitors PDE5i). Left Image: Courtesy of Abraham Morgentaler MD.
Risks of Testosterone Treatment Reviewed by Morgentaler
Dr Morgentaler 2004 NEJM article is also useful, covering the “Risks of testosterone-replacement therapy and recommendations for monitoring”. Dr Morgentaler says that 4 million men may be candidates for testosterone treatment, yet only 5 percent are actually treated. Even though there are no large scale, long term clinical studies looking at risks and adverse effects, the number of testosterone prescriptions have increased 500 percent since 1993.
Previous Studies Contradict Bhasin
In his 2004 report, Dr Morgentaler says that previous studies of testosterone-replacement have not shown increased of heart disease such as heart attacks, myocardial infarction, stroke, or angina. This is opposite to the findings of the Bhasin report. Increased blood count (Polycythemia) is an adverse effect noted in about 3% of men after testosterone treatment. This is controlled by reducing dosage or donating blood. Dr Morgentaler also discusses, prostate, PSA, sleep apnea, and other issues. He finds that testosterone treatment is not associated with increased prostate cancer, although he recommends prostate surveillance. Finally he discusses that a small percentage of men may note breast enlargement or tenderness from treatment. For more, take a look at Morgentaler’s 2009 book, Testosterone for Life: Recharge Your Vitality, Sex Drive, Muscle Mass, and Overall HealthLeft Image: Book Cover courtesy of Abraham Morgentaler MD
Conclusion: Testosterone therapy for immobilized elderly men with underlying chronic conditions such as obesity, heart disease, hypertension, and cigarette smoking is not recommended. However, for all other candidates for testosterone therapy, the health benefits clearly outweigh the risks and adverse effects which are quite manageable.
Articles With Related Content:
Links and References
N Engl J Med. 2010 Jul 8;363(2):109-22. Epub 2010 Jun 30.
Adverse events associated with testosterone administration.
Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin G, Hede-Brierley L, Bhatia A, Collins L, LeBrasseur N, Fiore LD, Bhasin S. Section of Endocrinology, Diabetes, and Nutrition, Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts 02118, USA.
BACKGROUND: Testosterone supplementation has been shown to increase muscle mass and strength in healthy older men. The safety and efficacy of testosterone treatment in older men who have limitations in mobility have not been studied.
METHODS: Community-dwelling men, 65 years of age or older, with limitations in mobility and a total serum testosterone level of 100 to 350 ng per deciliter (3.5 to 12.1 nmol per liter) or a free serum testosterone level of less than 50 pg per milliliter (173 pmol per liter) were randomly assigned to receive placebo gel or testosterone gel, to be applied daily for 6 months. Adverse events were categorized with the use of the Medical Dictionary for Regulatory Activities classification. The data and safety monitoring board recommended that the trial be discontinued early because there was a significantly higher rate of adverse cardiovascular events in the testosterone group than in the placebo group.
RESULTS: A total of 209 men (mean age, 74 years) were enrolled at the time the trial was terminated. At baseline, there was a high prevalence of hypertension, diabetes, hyperlipidemia, and obesity among the participants. During the course of the study, the testosterone group had higher rates of cardiac, respiratory, and dermatologic events than did the placebo group. A total of 23 subjects in the testosterone group, as compared with 5 in the placebo group, had cardiovascular-related adverse events. The relative risk of a cardiovascular-related adverse event remained constant throughout the 6-month treatment period. As compared with the placebo group, the testosterone group had significantly greater improvements in leg-press and chest-press strength and in stair climbing while carrying a load.
CONCLUSIONS: In this population of older men with limitations in mobility and a high prevalence of chronic disease, the application of a testosterone gel was associated with an increased risk of cardiovascular adverse events. The small size of the trial and the unique population prevent broader inferences from being made about the safety of testosterone therapy.
Testosterone Gel Trial Ends After Heart Issue By RONI CARYN RABIN
Published: July 5, 2010
The New York Times (7/6, D7, Rabin – reports, “A federally financed study to see if testosterone gel helps frail elderly men build muscle and strength was abruptly halted late last year after participants taking it suffered a disproportionate number of heart attacks and other serious cardiac problems, and one died of what was apparently a heart attack.” The Times says that “researchers were taken aback by the high rate of adverse heart problems.” The FDA “has approved it for use only in men with hypogonadism, whose sex glands produce extremely low amounts of testosterone or none at all because of an underlying disorder,” yet, “off-label use has increased in recent years.”
(3) EDITORIAL: Bremner WJ. Testosterone Deficiency and Replacement in Older Men. N Engl J Med;363(2):189-91.
Bloomberg News 07/21/2010 – More than one-fifth of patients using a testosterone gel sold by Auxilium Pharmaceuticals Inc. developed heart problems in a study of mobility-impaired men aged 65 and older.
The study found that 23 of 106, or 22 percent, of men getting the gel, Testim, had heart-related side effects such as chest pain, heart attack, stroke, or elevated blood pressure, according to a report published today in the New England Journal of Medicine. Of the 103 men who got a placebo, just five, or 5 percent, had similar adverse effects, the researchers at Boston University Medical Center found.
Testosterone supplements have been shown to boost muscle mass and strength in aging men, the report said. This trial was designed to see if Testim could improve physical function in men with limited mobility. While the testosterone group did show improvement in their ability to climb stairs and do leg presses, the study was halted early because of concern that the drug may be linked to cardiovascular problems.
“Physicians and patients, especially older men, should consider this study’s findings on adverse effects along with other information on the risks and benefits of testosterone therapy,” the study authors said in a statement. They urged further research “to clarify the safety issues raised by this trial.”
Testim had worldwide revenue of $160.5 million last year, 98 percent of the company’s total, according to a regulatory filing. Auxilium rose 65 cents, or 2.8 percent, to $23.50 in Nasdaq Stock Market composite trading at 4 p.m. New York time. The stock has declined 25 percent in the last 12 months.
Testim, a skin gel, was approved in October 2002 as a testosterone replacement therapy for men with hypogonadism, a condition in which the body doesn’t produce enough of the hormone. Hypogonadism can cause fatigue, infertility, decreased sex drive and loss of bone mass. Testim competes with Androgel, sold by Abbott Park, Illinois-based Abbott Laboratories.
The study, which was discontinued in December, was funded by a grant to Shalender Bhasin, the chief of endocrinology at Boston Medical Center, from the National Institute on Aging, part of the U.S. National Institutes of Health. Auxilium donated the product and wasn’t involved in the study design or execution, according to the report.
Twice as many men in the Testim group had complications requiring medical evaluations compared with the placebo group, according to the report. Ten men had full-blown cardiac events, including two confirmed heart attacks and one death.
Bhasin and his co-authors said aspects of this study make it difficult to draw conclusions about the safety of Testim. The main limitations they cited were the small size of the clinical trial and the nature of the population being studied.
Patients in the study were frail, had higher rates of chronic disease than the general population, and had an average age of 74, according to the study. In contrast, 95 percent of patients getting Testim in the real world are under 75, said Eboo Versi, vice president of drug safety and medical affairs of Malvern, Pennsylvania-based Auxilium.
Another factor that makes the findings not apply to other men is that some study participants were given 15 grams of Testim a day, while the medicine’s label recommends starting patients on 5 grams and going up to 10 grams only if needed. That dosing was “totally off label,” Versi said in a telephone interview today.
Overall in the study, 16 men received the highest dose or 15 grams of testosterone, while 61 received 10 grams and 29 received 5 grams, according to the journal report.
Another study of testosterone gel in men over 65, published online Jan. 8 in the Journal of Clinical Endocrinology & Metabolism, found no significant difference in cardiac events between the treatment group and those who got a placebo gel. Auxilium analyzed its Testim registration studies and didn’t find any increased risk of cardiovascular events, Versi said.
Corona, G., Mannucci, E., Ricca, V., Lotti, F., Boddi, V., Bandini, E., Balercia, G., Forti, G., & Maggi, M. (2009). The age-related decline of testosterone is associated with different specific symptoms and signs in patients with sexual dysfunction International Journal of Andrology, 32 (6), 720-728 DOI: 10.1111/j.1365-2605.2009.00952.x
Spetz, A., Palmefors, L., Skobe, R., Strmstedt, M., Fredriksson, M., Theodorsson, E., & Hammar, M. (2007). Testosterone correlated to symptoms of partial androgen deficiency in aging men (PADAM) in an elderly Swedish population
Menopause, PAP DOI: 10.1097/gme.0b013e318057786b
Allan, C., Forbes, E., Strauss, B., & McLachlan, R. (2008). Testosterone therapy increases sexual desire in ageing men with low–normal testosterone levels and symptoms of androgen deficiency International Journal of Impotence Research, 20 (4), 396-401 DOI: 10.1038/ijir.2008.22
Reyes-Vallejo, L., Lazarou, S., & Morgentaler, A. (2007). Subjective Sexual Response to Testosterone Replacement Therapy Based on Initial Serum Levels of Total Testosterone The Journal of Sexual Medicine, 4 (6), 1757-1762 DOI: 10.1111/j.1743-6109.2006.00381.x
Adverse Cardiovascular Events Reported in Testosterone Trial in Older Men Treatment Phase of Clinical Trial Halted
Increased Mortality and Low testosterone
Eur Heart J (2010) 31 (12): 1494-1501.
Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20–79,
Robin Haring1,2,*, Henry Völzke2, Antje Steveling3, Alexander Krebs1, Stephan B. Felix4, Christof Schöfl5, Marcus Dörr4, Matthias Nauck1 and Henri Wallaschofski1
Conclusion Low serum testosterone levels were associated with an increased risk of all-cause mortality independent of numerous risk factors. As serum testosterone levels are inversely related to mortality due to CVD and cancer, it may be used as a predictive marker.
Haring and colleagues add to the growing evidence of the importance of a link in a prospective population-based study (mean follow-up 7.2 years) showing in a sample of men aged 20–79 years that a testosterone level <8.7 nmol/L (250 ng/dL) doubled the risk of all-cause mortality independently of age, waist circumference, cigarette smoking, excess alcohol, and decreased physical activity.3
(6) Endogenous Testosterone and Mortality Due to All Causes, Cardiovascular Disease, and Cancer in Men European Prospective Investigation Into Cancer in Norfolk (EPIC-Norfolk) Prospective Population Study (Circulation. 2007;116:2694-2701.) 2007 American Heart Association, Inc. Endogenous testosterone mortality cardiovascular disease cancer men EPIC Khaw KayTee Circulation 2007
Conclusions— In men, endogenous testosterone concentrations are inversely related to mortality due to cardiovascular disease and all causes. Low testosterone may be a predictive marker for those at high risk of cardiovascular disease.
Vol. 166 No. 15, Aug 14/28, 2006
Low Serum Testosterone and Mortality in Male Veterans
Molly M. Shores, MD; Alvin M. Matsumoto, MD; Kevin L. Sloan, MD; Daniel R. Kivlahan, PhD
Arch Intern Med. 2006;166:1660-1665.
Anti-Anginal Heart Study
Low-Dose Transdermal Testosterone Therapy Improves Angina Threshold in Men With Chronic Stable Angina A Randomized, Double-Blind, Placebo-Controlled Study
Katherine M. English, MBChB, MRCP; Richard P. Steeds, MBBS, MRCP;
T. Hugh Jones, MD, MRCP; Michael J. Diver, PhD; Kevin S. Channer, MD, FRCP
Conclusions—Low-dose supplemental testosterone treatment in men with chronic stable angina reduces exercise-induced myocardial ischemia. (Circulation. 2000;102:1906-1911.)
Rosano GMC, Leonardo F, Pagnotta P, et al. Acute anti-ischemic effect
of testosterone in men with coronary artery disease. Circulation. 1999;
99:1666 –1670. Conclusions—Short-term administration of testosterone induces a beneficial effect on exercise-induced myocardial ischemia in men with coronary artery disease. This effect may be related to a direct coronary-relaxing effect.
Webb CM, Adamson DL, de Zeigler D, et al. Effect of acute testosterone
on myocardial ischemia in men with coronary artery disease. Am J
Cardiol. 1999;83:437– 439.
CLINICAL STUDY Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men Atish Mathur, Christopher Malkin, Basil Saeed1, R Muthusamy2, T Hugh Jones3,4 and Kevin Channer
Introduction: In short-term studies, testosterone replacement therapy has been shown to protect male subjects from exercise-induced ischaemia and modify cardiovascular risk factors such as insulin resistance, fat mass and lipid profiles.
Conclusion: The protective effect of testosterone on myocardial ischaemia is maintained throughout treatment without decrement. Previously noted potentially beneficial effects of testosterone on body composition were confirmed and there were no adverse effects.
Guideline for Male Testosterone Therapy: A Clinician’s Perspective
Abraham Morgentaler Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts The Journal of Clinical Endocrinology & Metabolism Vol. 92, No. 2 416-417 2007
N Engl J Med. 2004 Jan 29;350(5):482-92.
Risks of testosterone-replacement therapy and recommendations for monitoring.
Rhoden EL, Morgentaler A. Division of Urology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, USA.
J Sex Med. 2010 Jan;7(1 Pt 1):277-83.
Symptomatic response rates to testosterone therapy and the likelihood of completing 12 months of therapy in clinical practice. Rhoden EL, Morgentaler A. Men’s Health Boston, Division of Urology, Harvard Medical School, Boston, MA, USA.
INTRODUCTION: Despite increasing medical interest in testosterone therapy (TTh) for men with testosterone deficiency (TD) there is limited information regarding subjective response rates and acceptability of medium- to long-term TTh in routine clinical practice.
AIM: To evaluate results in a consecutive series of men in clinical practice treated with TTh.
MATERIAL AND METHODS: A chart review was performed for a consecutive series of men for whom TTh was initiated over 1 year for a clinical diagnosis of TD. A diagnosis of TD was based on the presence of symptoms and on laboratory evaluation indicating total testosterone (<300 ng/dL) or free testosterone (FT) (<1.5 ng/dL). Presenting symptoms were noted at baseline, and improvement was documented in domains of erectile function, libido, energy,and mood.
MAIN OUTCOME MEASURES: Percentage of men who completed 12 months of TTh, and symptomatic response rates.
RESULTS: There were 127 men included in the evaluation. The most common presenting symptoms were the combination of erectile dysfunction (ED) and reduced libido in 82 (64.6%), ED alone in 29 (22.8%), and reduced libido alone in 13 (10.2%). Initial mode of TTh was injections (testosterone enanthate or cypionate) in 70 (55.1%)and transdermal gel (Androgel, Solvay Pharmaceuticals, Marietta, GA, USA) in the remainder. Improvements in erections, libido, energy, and/or mood were reported by 70% of men by 3 months. Eighty men (63%) completed 12 months of TTh with subjective benefit (responders). Treatment was discontinued in 34 (26.8%) who reported no major benefit (non-responders), and 13 (10.2%) were lost to follow-up. Among men who discontinued TTh, 64.7%failed to report benefits by 3 months. Baseline FT was lower among responders than non-responders. One case(1.25%) of prostate cancer was identified after one year of TTh.
CONCLUSION: Approximately two-thirds of men with TD who begin TTh will experience symptomatic benefit and will complete at least 12 months of treatment. Benefit was noted in a majority by 3 months.
Calcium Score in Males on Testosterone
However, in a post hoc exploratory analysis of observed data restricted to statin non-users, the annual rate of change in coronary artery calcium was significantly lower in the testosterone group than in the placebo group (mean difference, −30.1; 95% CI, −59.1 to −1.0; P= .04).
In exploratory analyses, among statin nonusers, the rate of change in coronary artery calcium was lower in the testosterone group than in the placebo group; the opposite was found in statin users. These findings are similar to those reported in estradiol trials in postmenopausal women, in which estradiol’s effects on atherosclerosis were more strikingly apparent in statin nonusers than in statin users.14 Statin use is a marker of increased cardiovascular risk, and it is possible that the effects of testosterone may differ in older men at high risk of CVD. It is also possible that statin use masked a potentially beneficial effect of testosterone on atherosclerosis progression.
15) Basaria, Shehzad, et al. “Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels: a randomized clinical trial.” Jama 314.6 (2015): 570-581. TEAAM Testosterone 3 years Atherosclerosis older men with low testosterone Basaria Shehzad Jama 2015
Testosterone use in older men is increasing, but its long-term effects on
progression of atherosclerosis are unknown.
To determine the effect of testosterone administration on subclinical
atherosclerosis progression in older men with low or low-normal testosterone levels.
DESIGN, SETTING, AND PARTICIPANTS
Testosterone’s Effects on Atherosclerosis Progression in
Aging Men (TEAAM) was a placebo-controlled, double-blind, parallel-group randomized trial involving 308 men 60 years or older with low or low-normal testosterone levels (100-400 ng/dL; free testosterone <50 pg/mL), recruited at 3 US centers. Recruitment took place between
September 2004 and February 2009; the last participant completed the study in May 2012.
One hundred fifty-six participants were randomized to receive 7.5 g of 1%
testosterone and 152 were randomized to receive placebo gel packets daily for 3 years. The dose was adjusted to achieve testosterone levels between 500 and 900 ng/dL.
MAIN OUTCOMES AND MEASURES
Coprimary outcomes included common carotid artery intima-media thickness and coronary artery calcium; secondary outcomes included sexual function and health–related quality of life.
Baseline characteristics were similar between groups: patients were a mean age of 67.6 years; 42% had hypertension; 15%, diabetes; 15%, cardiovascular disease; and 27%, obesity. The rate of change in intima-media thickness was 0.010 mm/year in the placebo group and 0.012 mm/year in the testosterone group (mean difference adjusted for age and
trial site, 0.0002 mm/year; 95% CI, −0.003 to 0.003, P = .89).
The rate of change in the coronary artery calcium score was 41.4 Agatston units/year in the placebo group and 31.4 Agatston units/year in the testosterone group (adjusted mean difference, −10.8 Agatston units/year; 95% CI, −45.7 to 24.2;P= .54).
Changes in intima-media thickness or calcium scores were not associated with change in testosterone levels among individuals assigned to receive testosterone. Sexual desire, erectile function, overall sexual function scores, partner intimacy, and health-related quality of life did not differ significantly between groups.
Hematocrit and prostate-specific antigen levels increased more in testosterone group.
CONCLUSIONS AND RELEVANCE
Among older men with low or low-normal testosterone levels, testosterone administration for 3 years vs placebo did not result in a significant difference in the rates of change in either common carotid artery intima-media thickness or coronary artery calcium nor did it improve overall sexual function or health-related quality of life. Because this
16) Figure 6 supplement Basaria Showing Calcium Score in Statin Non-Users Basaria Testosterone heart Supplementary Figure 6 Calcium score statin non-users
Is Low T a marker for leaky gut? which is associated with atherosclersis?
17) Elagizi, Andrew, Tobias S. Köhler, and Carl J. Lavie. “testosterone and Cardiovascular Health.” Mayo Clinic Proceedings. Vol. 93. No. 1. Elsevier, 2018.
Studies involving men younger than 45 years with premature CAD have also found low testosterone levels in patients with CAD compared with controls.7 Although the correlations have been demonstrated with reproducible results, it is not possible to determine a cause-and-effect relationship. Testosterone levels may directly cause (or prevent) CAD and CVD events, or testosterone levels may simply be a marker of overall quality of health and have no direct effect on CAD and CVD events at all.
trial was only powered to evaluate atherosclerosis progression, these findings should not be interpreted as establishing cardiovascular safety of testosterone use in older men
It is clear that testosterone deficiency is associated with increased adverse CVD events, including mortality.12, 48, 51, 52 Although there are reports that suggest possible acceleration of coronary plaque progression with testosterone therapy,16 these findings must be reproduced before conclusions are drawn. A recent systematic review and meta-analysis by Alexander et al36 reviewed 39 randomized controlled trials and 10 observational studies and found that exogenous testosterone treatment, compared with placebo use, did not result in any significant increase in MI, stroke, or mortality.
Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial Chris J. Malkin1, Peter J. Pugh1, John N. West1, Edwin J.R. van Beek2, T. Hugh Jones4 and Kevin S. Channer1,3,*
Chronic heart failure is associated with maladaptive and prolonged neurohormonal and pro-inflammatory cytokine activation causing a metabolic shift favouring catabolism, vasodilator incapacity, and loss of skeletal muscle bulk and function. In men, androgens are important determinants of anabolic function and physical strength and also possess anti-inflammatory and vasodilatory properties.
Methods and results We conducted a randomized, double-blind, placebo-controlled parallel trial of testosterone replacement therapy (5 mg Androderm®) at physiological doses in 76 men (mean±SD, age 64±9.9) with heart failure (ejection fraction 32.5±11%) over a maximum follow-up period of 12 months. The primary endpoint was functional capacity as assessed by the incremental shuttle walk test (ISWT). At baseline, 18 (24%) had serum testosterone below the normal range and bioavailable testosterone correlated with distance walked on the initial ISWT (r=0.3, P=0.01). Exercise capacity significantly improved with testosterone therapy compared with placebo over the full study period (mean change +25±15 m) corresponding to a 15±11% improvement from baseline (P=0.006 ANOVA). Symptoms improved by at least one functional class on testosterone in 13 (35%) vs. 3 (8%) on placebo (P=0.01). No significant changes were found in handgrip strength, skeletal muscle bulk by cross-sectional computed tomography, or in tumour necrosis factor levels. Testosterone therapy was safe with no excess of adverse events although the patch preparation was not well tolerated by the study patients.
Conclusion Testosterone replacement therapy improves functional capacity and symptoms in men with moderately severe heart failure.
CLINICAL RESEARCH: HEART FAILURE
Testosterone Therapy in Women With Chronic Heart Failure A Pilot Double-Blind, Randomized, Placebo-Controlled Study Ferdinando Iellamo, MD*,,*, Maurizio Volterrani, MD*, Giuseppe Caminiti, MD*, Roger Karam, MD, Rosalba Massaro, MD*, Massimo Fini, MD*, Peter Collins, MD, PhD*, and Giuseppe M.C. Rosano, MD*
Objectives: The primary objective of this study was to assess the effect of a 6-month testosterone supplementation therapy on functional capacity and insulin resistance in female patients with chronic heart failure (CHF).
Background: Patients with CHF show decreased exercise capacity and insulin sensitivity. Testosterone supplementation improves these variables in men with CHF. No study has evaluated the effects of testosterone supplementation on female patients with CHF.
Methods: Thirty-six elderly female patients with stable CHF, (ejection fraction 32.9 ± 6) were randomly assigned (2:1 ratio) to receive testosterone transdermal patch (T group, n = 24) or placebo (P group, n = 12), both on top of optimal medical therapy. At baseline and after 6 months, patients underwent 6-min walking test (6MWT), cardiopulmonary exercise test, echocardiogram, quadriceps maximal isometric voluntary contraction, dynamic quadriceps isokinetic strength (peak torque), and insulin resistance assessment by homeostasis model.
Results: Distance walked at 6MWT as well as peak oxygen consumption significantly improved in the T group, whereas they were unchanged in the P group (p < 0.05 for all comparisons). The homeostasis model was significantly reduced in the T group in comparison with the P group (–16.5% vs. +5%, respectively; p < 0.05). Maximal voluntary contraction and peak torque increased significantly in the T group but did not change in the P group. Increase in distance walked at 6MWT was related to the increase in free testosterone levels (r = 0.593, p = 0.01). No significant changes in echocardiographic parameters were observed in either group. No side effects requiring discontinuation of T were detected.
Conclusions: Testosterone supplementation improves functional capacity, insulin resistance, and muscle strength in women with advanced CHF. Testosterone seems to be an effective and safe therapy for elderly women with CHF.
Circulation. 2006;114:1829-1837.) 2006 American Heart Association, Inc.
-Heart Failure Anabolic Deficiency in Men With Chronic Heart Failure
Prevalence and Detrimental Impact on Survival
Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism
in middle-aged and elderly men. N Engl J Med 2010; 363: 123-135.
Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with
testosterone administration. N Engl J Med 2010; 363: 109-122.
Liverman CT, Blazer DG, editors. Testosterone and aging: clinical
research directions. Washington, DC: Institute of Medicine, The National
Academies Press, 2004.
Kelleher S, Conway AJ, Handelsman DJ. Blood testosterone threshold
for androgen deficiency symptoms. J Clin Endocrinol Metab 2004; 89:
Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and
metabolic risks with serum testosterone in older men. J Clin Endocrinol
Metab 2006; 91: 4335-4343.
Travison TG, Shackelton R, Araujo AB, et al. The natural history of
symptomatic androgen deficiency in men: onset, progression, and spontaneous
remission. J Am Geriatr Soc 2008; 56: 831-839.
Travison TG, Araujo AB, Hall SA, McKinlay JB. Temporal trends in
testosterone levels and treatment in older men. Curr Opin Endocrinol
Diabetes Obes 2009; 16: 211-217.
Fernandez-Balsells MM, Murad MH, Lane M, et al. Clinical review 1:
adverse effects of testosterone therapy in adult men: a systematic review
and meta-analysis. J Clin Endocrinol Metab 2010; 95: 2560-2575.
Malkin CJ, Pugh PJ, West JN, et al. Testosterone therapy in men with
moderate severity heart failure: a double-blind randomized placebo
controlled trial. Eur Heart J 2006; 27: 57-64.
Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men
with androgen deficiency syndromes: an Endocrine Society clinical
practice guideline. J Clin Endocrinol Metab 2010; 95: 2536-2559.
Sikaris K, McLachlan RI, Kazlauskas R, et al. Reproductive hormone
reference intervals for healthy fertile young men: evaluation of automated
platform assays. J Clin Endocrinol Metab 2005; 90: 5928-5936.
Sartorius G, Ly LP, Sikaris K, et al. Predictive accuracy and sources of
variability in calculated free testosterone estimates. Ann Clin Biochem
2009; 46: 137-143.
European Male Ageing Study (EMAS).
J Sex Med. 2010 Apr;7(4 Pt 1):1362-80. Epub 2009 Nov 19.
Age-related changes in general and sexual health in middle-aged and older men: results from the European Male Ageing Study (EMAS). Andrology Unit, Department of Clinical Physiopathology, University of Florence, Florence, Italy.
Identification of Late-Onset Hypogonadism in Middle-Aged and Elderly Men
Frederick C.W. Wu, M.D., et al for the EMAS Group .
N Engl J Med 2010; 363:12 3-135 July 8, 2010
Testosterone Deficiency Slide Presentation by André T. Guay, MD, and Martin Miner, MD Testosterone Deficiency Slide Presentation by André T Guay MD and Martin Miner MD
Why Is Androgen Replacement in Males Controversial? Cunningham, Glenn R., and Shivani M. Toma. J Clin Endocrinol Metab 96.1 (2011): 38-52.
http://www.slate.com/id/2269042/ The Mel Gibson Excuse Does male menopause actually exist? By Jessica Dweck Sept. 30, 2010
Sunday October 3, 2010 The hormonal male Art of Healing By DR AMIR FARID ISAHAK The ins and outs of male sex hormones.
Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM, & Task Force, Endocrine Society (2010). Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. The Journal of clinical endocrinology and metabolism, 95 (6), 2536-59 PMID: 20525905
Araujo, A., Esche, G., Kupelian, V., O’Donnell, A., Travison, T., Williams, R., Clark, R., & McKinlay, J. (2007). Prevalence of Symptomatic Androgen Deficiency in Men Journal of Clinical Endocrinology & Metabolism, 92 (11), 4241-4247 DOI: 10.1210/jc.2007-1245
Testosterone: The New Anti-Aging Wonder Drug? by Rebecca Shatsky, MD 2011 |
Low serum testosterone and increased mortality in men with coronary heart disease by Chris J Malkin et al
Background: To examine the effect of serum testosterone levels on survival in a consecutive series of men with confirmed coronary disease and calculate the prevalence of testosterone deficiency. Patients 930 consecutive men with coronary disease referred for diagnostic angiography recruited between June 2000 and June 2002 and followed up for a mean of 6.9±2.1 years. Outcome: All-cause mortality and vascular mortality. Prevalence of testosterone deficiency. Results: The overall prevalence of biochemical testosterone deficiency in the coronary disease cohort using bio-available testosterone (bio-T) <2.6 nmol/l was 20.9%, using total testosterone <8.1 nmol/l was 16.9% and using either was 24%.
Excess mortality was noted in the androgen-deficient group compared with normal (41 (21%) vs 88 (12%), p=0.002). The only parameters found to influence time to all-cause and vascular mortality (HR ± 95% CI) in multivariate analyses were the presence of left ventricular dysfunction (3.85; 1.72 to 8.33), aspirin therapy (0.63; 0.38 to 1.0), β-blocker therapy (0.45; 0.31 to 0.67) and low serum bio-T (2.27; 1.45 to 3.6).
Conclusions In patients with coronary disease testosterone deficiency is common and impacts significantly negatively on survival. Prospective trials of testosterone replacement are needed to assess the effect of treatment on survival.
Disclaimer click here: www.drdach.com/wst_page20.html
The reader is advised to discuss the comments on these pages with his/her personal physicians and to only act upon the advice of his/her personal physician. Also note that concerning an answer which appears as an electronically posted question, I am NOT creating a physician — patient relationship. Although identities will remain confidential as much as possible, as I can not control the media, I can not take responsibility for any breaches of confidentiality that may occur.
Link to this article:http://wp.me/p3gFbV-SR
Copyright (c) 2013 Jeffrey Dach MD All Rights Reserved. This article may be reproduced on the internet without permission, provided there is a link to this page and proper credit is given.
FAIR USE NOTICE: This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of issues of significance. We believe this constitutes a ‘fair use’ of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes.